BRCA1 and breast carcinoma: Inhibition of PARP‐1 leads to inadequate function of the DDR repair system and inhibits replication in breast cancer genes 1 and 2 (BRCA1/2) protein‐deficient cancer cells, a concept known as “synthetic lethality” [3, 4].